AU2018301651B2 - A peptide saporin conjugate for the treatment of cancer - Google Patents

A peptide saporin conjugate for the treatment of cancer Download PDF

Info

Publication number
AU2018301651B2
AU2018301651B2 AU2018301651A AU2018301651A AU2018301651B2 AU 2018301651 B2 AU2018301651 B2 AU 2018301651B2 AU 2018301651 A AU2018301651 A AU 2018301651A AU 2018301651 A AU2018301651 A AU 2018301651A AU 2018301651 B2 AU2018301651 B2 AU 2018301651B2
Authority
AU
Australia
Prior art keywords
mgs
peptides
ala
peptide
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018301651A
Other languages
English (en)
Other versions
AU2018301651A1 (en
Inventor
Curtis Allred
Kathlynn C. Brown
Michael Mcguire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
Original Assignee
SRI International Inc
Stanford Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc, Stanford Research Institute filed Critical SRI International Inc
Publication of AU2018301651A1 publication Critical patent/AU2018301651A1/en
Application granted granted Critical
Publication of AU2018301651B2 publication Critical patent/AU2018301651B2/en
Priority to AU2023216858A priority Critical patent/AU2023216858A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018301651A 2017-07-10 2018-07-10 A peptide saporin conjugate for the treatment of cancer Active AU2018301651B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023216858A AU2023216858A1 (en) 2017-07-10 2023-08-17 A peptide saporin conjugate for the treatment of cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530674P 2017-07-10 2017-07-10
US62/530,674 2017-07-10
PCT/US2018/041412 WO2019014199A1 (en) 2017-07-10 2018-07-10 PEPTIDE SAPORIN CONJUGATE FOR THE TREATMENT OF CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023216858A Division AU2023216858A1 (en) 2017-07-10 2023-08-17 A peptide saporin conjugate for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2018301651A1 AU2018301651A1 (en) 2020-01-30
AU2018301651B2 true AU2018301651B2 (en) 2023-05-18

Family

ID=65002607

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018301651A Active AU2018301651B2 (en) 2017-07-10 2018-07-10 A peptide saporin conjugate for the treatment of cancer
AU2023216858A Pending AU2023216858A1 (en) 2017-07-10 2023-08-17 A peptide saporin conjugate for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023216858A Pending AU2023216858A1 (en) 2017-07-10 2023-08-17 A peptide saporin conjugate for the treatment of cancer

Country Status (6)

Country Link
US (1) US11738089B2 (enExample)
EP (1) EP3652195A4 (enExample)
JP (2) JP2020527556A (enExample)
CN (2) CN111417646B (enExample)
AU (2) AU2018301651B2 (enExample)
WO (1) WO2019014199A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018301804B2 (en) 2017-07-10 2024-07-25 Sri International Molecular guide system peptides and uses thereof
US11738089B2 (en) 2017-07-10 2023-08-29 Sri International Peptide saporin conjugate for the treatment of cancer
US20240024495A1 (en) * 2017-07-10 2024-01-25 Sri International A peptide saporin conjugate for the treatment of cancer
JP2023503797A (ja) * 2019-10-01 2023-02-01 キャスリン シー ブラウン 分子ガイドシステムペプチド及びその使用
WO2023122632A1 (en) * 2021-12-21 2023-06-29 Sri International Dual targeting for cell-specific delivery to the central nervous system
EP4490298A1 (en) * 2022-03-09 2025-01-15 Ospedale San Raffaele S.r.l. Fusion proteins and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140094404A1 (en) * 2011-01-13 2014-04-03 Antonio Pedro Villaverde Corrales Methods and reagents for efficient and targeted delivery of therapeutic molecules to cxcr4 cells
US9068187B1 (en) * 2010-02-09 2015-06-30 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
WO2018114798A1 (de) * 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
CA2826735C (en) 2003-04-30 2019-06-04 University Of Zurich Methods for treating cancer using an immunotoxin
JP2007528725A (ja) * 2004-02-20 2007-10-18 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 結合ペルオキシダーゼ模倣物及びその使用
EP1867661A1 (en) 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
WO2009089186A2 (en) * 2008-01-05 2009-07-16 Sloan-Kettering Institute For Cancer Research Peptide-conjugated oligonucleotide therapeutic and method of making and using same
US8362207B2 (en) 2010-04-16 2013-01-29 Wake Forest University Health Sciences Multi-level specific targeting of cancer cells with IL-13
US9062312B2 (en) 2011-06-21 2015-06-23 Danisco Us Inc. Fusion peptides comprising multi-functional peptidic solubility tags for efficient production, processing and surface applications
EP3677285B1 (en) 2014-08-04 2023-12-13 Case Western Reserve University Targeting peptides for detecting prostate cancer
US11080595B2 (en) 2016-11-04 2021-08-03 Salesforce.Com, Inc. Quasi-recurrent neural network based encoder-decoder model
US20180157388A1 (en) 2016-12-02 2018-06-07 Google Inc. Emotion expression in virtual environment
US11738089B2 (en) 2017-07-10 2023-08-29 Sri International Peptide saporin conjugate for the treatment of cancer
AU2018301804B2 (en) 2017-07-10 2024-07-25 Sri International Molecular guide system peptides and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9068187B1 (en) * 2010-02-09 2015-06-30 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US20140094404A1 (en) * 2011-01-13 2014-04-03 Antonio Pedro Villaverde Corrales Methods and reagents for efficient and targeted delivery of therapeutic molecules to cxcr4 cells
WO2018114798A1 (de) * 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BENJAMIN J UMLAUF ET AL, "Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8+ T-cell Activation Against Tumors", MOLECULAR THERAPY, US, (2015-06-01), vol. 23, no. 6, pages 1092 - 1102 *
BENJAMIN J. UMLAUF ET AL, "Identification of a Novel Lysosomal Trafficking Peptide using Phage Display Biopanning Coupled with Endocytic Selection Pressure", BIOCONJUGATE CHEMISTRY, US, (2014-10-15), vol. 25, no. 10, pages 1829 - 1837 *
GIANSANTI F. ET AL, "PDZ Domain in the Engineering and Production of a Saporin Chimeric Toxin as a Tool for targeting Cancer Cells : PDZ-MEDIATED TARGETING OF SAPORIN TOXIN", JOURNAL OF CELLULAR BIOCHEMISTRY, 2015, vol. 116, pages 1256-1266 *
KUANG HUIHUI ET AL, "The design of peptide-amphiphiles as functional ligands for liposomal anticancer drug and gene delivery", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, (2016-08-16), vol. 110, pages 80 - 101 *
MICHAEL J. MCGUIRE ET AL, "Identification and Characterization of a Suite of Tumor Targeting Peptides for Non-Small Cell Lung Cancer", SCIENTIFIC REPORTS, (2014-03-27), vol. 4, no. 1, doi:10.1038/srep04480, pages 1 - 11 *
ZHOU XIN ET AL, "Cell-specific delivery of a chemotherapeutic to lung cancer cells", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, US, (2004-12-08), vol. 126, no. 48, pages 15656 - 15657 *

Also Published As

Publication number Publication date
EP3652195A1 (en) 2020-05-20
US11738089B2 (en) 2023-08-29
WO2019014199A1 (en) 2019-01-17
CN111417646B (zh) 2024-04-19
EP3652195A4 (en) 2021-08-04
US20220226487A1 (en) 2022-07-21
CN118240025A (zh) 2024-06-25
JP2024012517A (ja) 2024-01-30
AU2023216858A1 (en) 2023-11-09
AU2018301651A1 (en) 2020-01-30
JP2020527556A (ja) 2020-09-10
CN111417646A (zh) 2020-07-14

Similar Documents

Publication Publication Date Title
AU2018301651B2 (en) A peptide saporin conjugate for the treatment of cancer
JP7742390B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP7627726B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP6510410B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP7642700B2 (ja) 分子誘導システムペプチド及びその使用
US9757473B2 (en) Cell-penetrating peptide and conjugate comprising same
CN109563151A (zh) 用于治疗癌症的方法和组合物
JP2025166082A (ja) 分子ガイドシステムペプチド及びその使用
WO2015070210A1 (en) Epha3 and multi-valent targeting of tumors
KR20210009192A (ko) 항암활성을 갖는 면역조절 단백질-siRNA 복합체
KR102166549B1 (ko) 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
US20240024495A1 (en) A peptide saporin conjugate for the treatment of cancer
CN116390768B (zh) 具有抗癌活性的免疫调节蛋白-siRNA复合物
US20250228951A1 (en) Novel-peptide-based anticancer immunotherapeutic agent
CN102656186A (zh) 治疗剂
US20220096594A1 (en) Macrocyclic peptides for targeted inhibition of autophagy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)